Merck KGaA Draws A Line Under “Old” R&D, Now Seeks More Deals

Germany’s Merck KGaA has streamlined its R&D pipeline, concentrating on immuno-oncology, early-stage compounds and collaborative efforts with partners, and discontinuing expensive late-stage products that were going nowhere.